As market pressures have increased, the pace of M&A consolidation in the medical device industry has accelerated.

However, the game-changing megamergers may be behind us.

Related Company Profiles

View all

The only milestone merger that happened in 2016 in medical technology was Abbott Laboratories’ acquisition of St. Jude for $25bn.

Other key multibillion-dollar deals so far this year have been Abbott’s buyout of Alere for $5.8bn, Canon’s acquisition of Toshiba Medical Systems for $5.9bn, and Johnson & Johnson’s acquisition of Abbott Medical Optics from Abbott Laboratories for $4.3bn.

While large, transformative transactions are rare, the trend towards strategic merger and acquisition activities at a tuck-in level in medtech continued in 2016.

In fact, medical device companies have demonstrated an increasing appetite for strategic so-called bolt-on acquisitions that would fill their portfolio gaps and and give them better geographical reach.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For example, Thermo Fisher has been pursuing a steady M&A strategy in its life sciences business and secured a string of bolt-on deals in 2016 alone. The acquisitions of biological analysis toolmaker Affymetrix; leading high-performance electron microscopy provider FEI; and a stem cell and reagent firm, MTI-GlobalStem to name a few.

This year, although the new landscape favours large companies who can leverage economies of scale, there’s likely to be a calming of the high-profile M&A scene.

Instead, the shift to strategic M&A activities at a tuck-in level will continue.

Allergan’s acquisition of Zeltiq ($2.5bn) in February is a good example of companies leveraging existing competitive advantages and seeking inorganic growth through more focused M&As that are complementary and strategic.

By adding the body contouring CoolSculpting System to Allergan’s facial aesthetics, plastic surgery and regenerative medicine offerings, the company is poised to create a world-class aesthetics business.